Key result
Rivaroxaban reduced deep vein thrombosis compared to enoxaparin following total hip replacement, whereas dabigatran showed comparable efficacy and safety to enoxaparin.
Why the study?
Does rivaroxaban or dabigatran reduce thromboembolism compared to enoxaparin in patients undergoing total hip or knee replacement?
Systematic Review
Does rivaroxaban or dabigatran reduce thromboembolism compared to enoxaparin in patients undergoing total hip or knee replacement?
Dabigatran and rivaroxaban show comparable overall efficacy and safety to enoxaparin for thromboprophylaxis after hip and knee replacement, though rivaroxaban significantly reduces DVT at the cost of increased major bleeding in hip replacement.
Answers are grounded in this paper and cite their sources.
Rivaroxaban may be considered for superior DVT prevention after hip replacement despite bleeding risk; extends meta-analytic support for NOACs versus enoxaparin.
OBJECTIVES: Due to a high risk of thromboembolism in patients undergoing major orthopedic surgery, it has become standard practice to give thromboprophylactic treatment. We assessed the relative efficacy and cost-effectiveness of two new oral anticoagulants, rivaroxaban and dabigatran, relative to subcutaneous enoxaparin for the prevention of thromboembolism after total hip replacement (THR) and total knee replacement surgery (TKR). METHODS: We conducted a systematic review of the literature to assess efficacy and safety, and evaluated quality of documentation using GRADE. Cost-effectiveness was assessed by developing a decision model. The model combined two modules; a decision tree for the short-term prophylaxis and a Markov model for the long-term complications and survival gain. RESULTS: For rivaroxaban compared with enoxaparin, we found statistically significant decreases in deep vein thrombosis, but also a trend toward increased risk of major bleeding. For mortality and pulmonary embolism there were no statistically significant differences between the treatments. We did not find statistically significant differences between dabigatran and enoxaparin for our efficacy and safety outcomes. Assuming a willingness to pay of EUR62,500 per QALY, rivaroxaban following THR had a probability of 38 percent, and enoxaparin following TKR had a probability of 34 percent of being cost-effective. Clinical efficacy had the greatest impact on decision uncertainty. CONCLUSIONS: Dabigatran and rivaroxaban are comparable with enoxaparin following THR and TKR regarding the efficacy and safety outcomes. However, there is great uncertainty regarding which strategy is the most cost-effective. More research on clinical efficacy of rivaroxaban and dabigatran is likely to change our results.
No takes yet. Share an insight, caveat, or question.
Hamidi et al. (2013) conducted a systematic review in Venous thromboembolism after total hip or knee replacement. Rivaroxaban and Dabigatran vs. Subcutaneous enoxaparin was evaluated on Deep vein thrombosis (DVT) following total hip replacement (Rivaroxaban vs Enoxaparin) (RR 0.21, 95% CI 0.14 to 0.32). Rivaroxaban reduced deep vein thrombosis compared to enoxaparin following total hip replacement, whereas dabigatran showed comparable efficacy and safety to enoxaparin.
Synapse has enriched 10 related papers. Consider them for comparative context: